UBS Group
ALXO icon

UBS Group’s ALX Oncology ALXO Stock Holding History

UBS Group’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$958K Sell
462,943
-451,811
-49% -$809K ﹤0.01% 5773
2026
Q1 		$1.83M Buy
914,754
+48,763
+6% +$92.9K ﹤0.01% 5054
2025
Q4 		$979K Buy
865,991
+693,421
+402% +$1.05M ﹤0.01% 5598
2025
Q3 		$316K Sell
172,570
-116,115
-40% -$101K ﹤0.01% 6409
2025
Q2 		$120K Buy
288,685
+32,192
+13% +$16.2K ﹤0.01% 7079
2025
Q1 		$160K Sell
256,493
-151,563
-37% -$182K ﹤0.01% 6705
2024
Q4 		$681K Buy
408,056
+378,816
+1,296% +$582K ﹤0.01% 5630
2024
Q3 		$53.2K Buy
29,240
+13,787
+89% +$51.3K ﹤0.01% 6780
2024
Q2 		$93.2K Sell
15,453
-13,621
-47% -$167K ﹤0.01% 6207
2024
Q1 		$324K Sell
29,074
-1,914
-6% -$26.9K ﹤0.01% 5518
2023
Q4 		$461K Buy
30,988
+19,794
+177% +$188K ﹤0.01% 5171
2023
Q3 		$53.7K Sell
11,194
-1,168
-9% -$6.34K ﹤0.01% 6251
2023
Q2 		$92.8K Buy
12,362
+2,319
+23% +$15.2K ﹤0.01% 6071
2023
Q1 		$45.4K Buy
10,043
+2,801
+39% +$21.2K ﹤0.01% 6528
2022
Q4 		$81.6K Buy
+7,242
New +$81.3K ﹤0.01% 6290
2022
Q2 		– Sell
-86,072
Closed -$1.46M – 10261
2022
Q1 		$1.46M Sell
86,072
-7,726
-8% -$132K ﹤0.01% 3745
2021
Q4 		$2.02M Buy
93,798
+86,532
+1,191% +$3.73M ﹤0.01% 3723
2021
Q3 		$537K Buy
7,266
+2,528
+53% +$168K ﹤0.01% 4685
2021
Q2 		$259K Sell
4,738
-14,210
-75% -$850K ﹤0.01% 5171
2021
Q1 		$1.4M Buy
18,948
+18,898
+37,796% +$1.49M ﹤0.01% 3907
2020
Q4 		$4K Buy
+50
New +$3.01K ﹤0.01% 7891

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

UBS Group's ALXO Position: Q2 2026 in Review

UBS Group reduced its ALX Oncology (ALXO) stake by 49% in Q2 2026, selling an estimated $809K and leaving 462,943 shares worth $958K. The position accounts for ﹤0.01% of the portfolio, ranked #5773.

UBS Group first reported a position in ALXO in Q4 2020 and has held it in 21 quarters since. The position peaked at $2.02M in Q4 2021. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • UBS Group held 462,943 shares of ALX Oncology worth $958K as of Q2 2026.
  • UBS Group sold 451,811 ALX Oncology shares in Q2 2026, an estimated $809K.
  • ALX Oncology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5773 holding.
  • UBS Group first reported a position in ALX Oncology in Q4 2020 and has held it in 21 quarters since.
  • UBS Group's ALX Oncology position peaked at $2.02M in Q4 2021.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.